<DOC>
	<DOCNO>NCT00795730</DOCNO>
	<brief_summary>This multiple dose study NSA-789 , purpose ass safety tolerability healthy subject subject Alzheimer 's Disease</brief_summary>
	<brief_title>Multiple Dose Study Evaluating Safety Tolerability NSA-789</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Inclusion Criteria Men woman age 18 50 year ( healthy subject ) great 55 year old ( subject Alzheimer 's Disease ) Women must surgically sterile postmenopausal Subjects Alzheimer 's Disease must generally healthy , may stable , chronic illness well control . Exclusion Criteria Healthy subject may prescription investigation drug within 30 day start study . Subjects Alzheimer 's Disease may cholinesterase inhibitor donepezil ( Aricept® ) rivastigmine ( Exelon® ) within 4 week start study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>schizophrenia</keyword>
</DOC>